A switch to anastrozole increases the efficacy of adjuvant therapy for breast cancer
This article has no abstract so we have provided the first paragraph of the full text.
Five years of tamoxifen has long been the standard adjuvant therapy for women with hormone-sensitive early-stage breast cancer; however, tamoxifen is associated with a number of adverse effects, and certain patients seem to develop resistance to this agent. Thus, a number of specialty guidelines now recommend switching patients to anastrozole therapy after 2–3 years of adjuvant tamoxifen.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.